Pfizer and Innovent Biologics secured spots on China's state reimbursement list for their GLP-1 diabetes treatments starting January 1. The additions intensify competition for Novo Nordisk A/S-B in the world's largest population of adults with type 2 diabetes. Inclusion on the national insurance scheme expands market reach, though suppliers typically accept lower prices in exchange for volume.

Expanding Access in Diabetes Care